BR112019018388A2 - método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno - Google Patents

método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno Download PDF

Info

Publication number
BR112019018388A2
BR112019018388A2 BR112019018388A BR112019018388A BR112019018388A2 BR 112019018388 A2 BR112019018388 A2 BR 112019018388A2 BR 112019018388 A BR112019018388 A BR 112019018388A BR 112019018388 A BR112019018388 A BR 112019018388A BR 112019018388 A2 BR112019018388 A2 BR 112019018388A2
Authority
BR
Brazil
Prior art keywords
dosage form
film
fact
oral
mtl
Prior art date
Application number
BR112019018388A
Other languages
English (en)
Portuguese (pt)
Inventor
G Zerbe Horst
W Conway Justin
Paiement Nadine
Obeid Rodolphe
Original Assignee
Intelgenx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intelgenx Corp filed Critical Intelgenx Corp
Publication of BR112019018388A2 publication Critical patent/BR112019018388A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019018388A 2017-03-30 2018-03-29 método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno BR112019018388A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478876P 2017-03-30 2017-03-30
PCT/CA2018/050389 WO2018176149A1 (en) 2017-03-30 2018-03-29 Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists

Publications (1)

Publication Number Publication Date
BR112019018388A2 true BR112019018388A2 (pt) 2020-04-07

Family

ID=63673863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018388A BR112019018388A2 (pt) 2017-03-30 2018-03-29 método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno

Country Status (9)

Country Link
EP (1) EP3600265A1 (de)
JP (1) JP2020512309A (de)
KR (1) KR20190128637A (de)
CN (1) CN110381931A (de)
AU (1) AU2018241534A1 (de)
BR (1) BR112019018388A2 (de)
CA (1) CA3056944A1 (de)
MX (1) MX2019010573A (de)
WO (1) WO2018176149A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150213A1 (en) * 2018-09-14 2022-03-19 Intelgenx Corp. TREATMENT METHOD AND DEVICE FOR ENHANCED BIOAVAILABILITY OF MONTELUKAST, A LEUCOTRIEN RECEPTOR ANTAGONIST
US20210393611A1 (en) * 2018-11-05 2021-12-23 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US11602504B2 (en) * 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
CN110496124A (zh) * 2019-04-10 2019-11-26 中山大学附属第五医院 治疗脉管畸形的化合物
CN114931578A (zh) * 2022-05-16 2022-08-23 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 孟鲁司特在制备用于治疗***性红斑狼疮药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
KR101077468B1 (ko) * 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
EA038558B1 (ru) * 2013-10-14 2021-09-14 Зим Лэбораториз Лимитед Водорастворимая фармацевтическая пленка с повышенной стабильностью
US9668970B2 (en) * 2013-12-02 2017-06-06 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
CN104784157B (zh) * 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂

Also Published As

Publication number Publication date
JP2020512309A (ja) 2020-04-23
AU2018241534A1 (en) 2019-09-26
CA3056944A1 (en) 2018-10-04
KR20190128637A (ko) 2019-11-18
EP3600265A1 (de) 2020-02-05
CN110381931A (zh) 2019-10-25
MX2019010573A (es) 2019-10-24
WO2018176149A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
BR112019018388A2 (pt) método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno
US10722476B2 (en) Device and method of treating conditions associated with neuroinflammation
US20220395452A1 (en) Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
US20230201130A1 (en) Lipophilic active oral film formulation and method of making the same
CN107567440B (zh) 焦谷氨酸沃替西汀
US20220362164A1 (en) Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
CN114272233A (zh) 一种奥司他韦组合物及其制备方法
CA3017526A1 (en) Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
EP3849553A1 (de) Behandlungsverfahren und vorrichtung zur verbesserten bioverfügbarkeit von montelukast, einem leukotrienrezeptorantagonist
US20210393611A1 (en) Lipophilic active oral film formulation and method of making the same
US11690829B2 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
Peter et al. DESIGN AND EVALUATION OF CARBAMAZEPINE LOZENGES
JPWO2021062061A5 (de)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]